Aprea Therapeutics (APRE) vs Skye Bioscience (SKYE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Skye Bioscience is the larger company by market cap ($7.4 million vs $7.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | APRE | SKYE |
|---|---|---|
| Share price | $0.5582 | $1.68 |
| Market cap | $7.03M | $7.44M |
| 1-day change | -7.74% | +1.82% |
| EPS (TTM) | $-0.95 | $-10.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.69 | $14.08 |
| 52-week low | $0.548 | $1.50 |
| Distance from 52-week high | -66.97% | -88.07% |
| Analyst consensus | none | none |
| Avg. price target upside | +568.22% | +3947.62% |
| Average volume | 277.08K | 89.05K |
| Shares outstanding | 12.59M | 4.43M |
| Employees | 8 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aprea Therapeutics
APRE stock →Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Healthcare · Biotechnology · 8 employees
About Skye Bioscience
SKYE stock →Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Healthcare · Biotechnology · 2 employees
APRE vs SKYE FAQ
Which is bigger, Aprea Therapeutics or Skye Bioscience?
Skye Bioscience (SKYE) is larger, with a market capitalization of $7.44M compared with $7.03M for Aprea Therapeutics (APRE).
Are Aprea Therapeutics and Skye Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.